Adverse reactions induced by teriparatide

doi:10.19803/j.1672-8629.2022.03.23

Abstract

Abstract: Objective To analyze the patterns and characteristics of adverse reactions induced by teriparatide and to provide guidance for its rational use in clinic. Methods Domestic and foreign journals published between January 1, 2002 and March 31, 2020 were retrieved to collect data on cases of adverse reaction induced by teriparatide before statistical analysis. Results A total of 20 adverse reactions reported by 17 articles were collected, involving musculo-skeletal system disorders, metabolic and nutritional disorders and skin damage. Most of the adverse reactions were cured soon after discontinuation of medication, but musculo-skeletal system disorders might take months to cure or persist throughout one’s life. Conclusion Before prescribing teriparatide, doctors should find out about the basic biochemical indicators, such as blood calcium, phosphorus, alkaline phosphatase and creatinine and make sure that patients with bone malignant tumors, bone metastases, and at high risk of osteosarcoma are excluded from use.

Key words: teriparatide, parathyroid hormone, osteoporosis, adverse reactions

CLC Number:

R994.11

CUI Can, WEI Hongtao, CHENG Sheng, SHEN Su. Adverse reactions induced by teriparatide[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 333-335.

References

[1] CHEN JF, YANG KH, ZHANG ZL, et al.A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia[J]. Osteoporos Int, 2015, 26(1): 11-28.
[2] ELRAIYAH T, GIONFRIDDO MR, MURAD MH.Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide[J]. J Clin Epidemiol, 2015, 68(6): 698-702.
[3] Osteoporosis and bone mineral disease branch of Chinese medical association. Guidelines for diagnosis and treatment of primary osteoporosis(2017)[J]. CHIN J Osteoporosis & Bone Mineral Res(中华骨质疏松和骨矿盐疾病杂志), 2017, 38(2): 127-150.
[4] PANDIT A, KHARB S, GARG MK.Raised CA19.9 and hepatic space occupying lesion after teriparatide therapy in a case of polyostotic fibrous dysplasia[J]. Indian J Endocrinol Metab, 2013, 17(5): 947-949.
[5] THIRUCHELVAM N, RANDHAWA J, SADIEK H, et al. Teriparatide induced delayed persistent hypercalcemia[J/OL]. (2014-06-13)[2014-08-18]. 802473.https://www.hindawi.com/journals/crie/2014/802473/.
[6] ROSCHGER P, RINNERTHALER S, YATES J, et al.Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women[J]. Bone, 2001, 29(2): 185-191.
[7] HAJIME M, OKADA Y, MORI H, et al.A case of teriparatide-induced severe hypophosphatemia and hypercalcemia[J]. J Bone Miner Metab, 2014, 32(5): 601-604.
[8] KARATOPRAK C, KAYATAS K, KILICASLAN H, et al.Severe hypercalcemia due to teriparatide[J]. Indian J Pharmacol, 2012, 44(2): 270-271.
[9] AYASREH N, FERNANDEZ-LLAMA P, LLORET MJ, et al.Recombinant PTH associated with hypercalcaemia and renal failure[J]. Clin Kidney J, 2013, 6(1): 93-95.
[10] KHARB S, GUNDGURTHI A, PANDIT A, et al.Hypercalcemic encephalopathy due to milk alkali syndrome and injection teriparatide[J]. Indian J Endocrinol Metab, 2012, 16(6): 1026-1028.
[11] LICATA AA.Osteoporosis, teriparatide, and dosing of calcium and vitamin D[J]. N Engl J Med, 2005, 352(18): 1930-1931.
[12] KAKARIA PJ, NASHEL DJ, NYLEN ES.Debilitating muscle cramps after teriparatide therapy[J]. Ann Intern Med, 2005, 142(4): 310-317.
[13] LUIGETTI M, CAPONE F, MONFORTE M, et al.Muscle cramps and weakness after teriparatide therapy: a new drug-induced myopathy?[J]. Muscle Nerve, 2013, 47(4): 615-623.
[14] BIAN PD, PAN HW.Leg muscle cramps induced by teriparatide in three osteoporosis women[J] Chin J New Drugs Clin Rem(中国新药与临床杂志), 2015, 34(1): 77-78.
[15] ECHEVERRI AF, OSPINA FE, CANAS CA, et al.Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients[J]. Br J Dermatol, 2016, 175(5): 1049-1051.
[16] HEARD LK, RICHARDSON VN, LEWIS CM, et al.A case of autoinflammatory skin and bone disease flared by a change in osteop-orosis management[J]. JAAD Case Rep, 2017, 3(2): 103-105.
[17] CHU H, KIM DS.Eczematous dermatitis due to subcutaneous teriparatide injection[J]. Endocrine, 2016, 52(2): 395-396.
[18] HARPER KD, KREGE JH, MARCUS R, et al.Osteosarcoma and teriparatide?[J]. J Bone Miner Res, 2007, 22(2): 334-335.
[19] OGAWA T, OHSHIKA S, YANAGISAWA M, et al.Teriparatide may accelerate the growth of a pre-existing malignant tumor in an elderly patient with osteoporosis: a case report[J]. Mol Clin Oncol, 2020, 12(2): 144-147.
[20] SUBBIAH V, MADSEN VS, RAYMOND AK, et al.Of mice and men: divergent risks of teriparatide-induced osteosarcoma[J]. Osteoporos Int, 2010, 21(6): 1041-1045.
[21] PAL R, AGRAWAL K, GUPTA S, et al.Worsening of unrecognized tumour-induced osteomalacia with inadvertent use of recombinant human parathyroid hormone[J]. Endokrynol Pol, 2020, 71(1): 102-103.
[22] GILSENAN A, HARDING A, KELLIER-STEELE N, et al.The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years[J]. Osteoporos Int, 2018, 29(10): 2335-2343.
[23] NISHIKAWA A, ISHIDA T, TAKETSUNA M, et al.Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report[J]. Clin Interv Aging, 2016, 11: 913-925.
[24] ZIFFRA JB, Jr., Olshansky B. Teriparatide-induced atrial tachycardia[J/OL]. BMJ Case Rep, 2018, 1-3 [2018-01-30].http://dx.doi.org/10.1136/bcr-2017-223035.
[25] ENISHI T, UEMURA H, KATOH S, et al.Transient severe hypotension with once-weekly subcutaneous injection of teriparatide in osteoporotic patient: a case report and insight for the drug interaction between hypotensive agents and teriparatide[J]. J Med Invest, 2015, 62(1-2): 93-96.
[26] CAI Y.A case of anaphylactic shock caused by teriparatide[J].Pharmaceutical & Clin Res(药物与临床研究), 2015, (6): 601-601.